Screener
Stoke Therapeutics, Inc. STOK Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Stoke Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The source filing: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211874
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Diluted | (0.79) | 1.90 |
| Weighted-average common shares outstanding: | ||
| Basic | 63,063,507 | 57,862,674 |
| Diluted | 63,063,507 | 59,398,600 |
| Comprehensive (loss) income: | ||
| Net (loss) income | $(50,003) | $112,879 |
| Other comprehensive (loss) gain: | ||
| Unrealized (loss) gain on marketable securities | (658) | 47 |
Item 1. Financial Statements.
FAQ
- What is Stoke Therapeutics, Inc.'s shares (diluted)?
- Stoke Therapeutics, Inc. (STOK) reported shares (diluted) of 63.1M in Q1 2026.
- How has Stoke Therapeutics, Inc.'s shares (diluted) changed year-over-year?
- Stoke Therapeutics, Inc.'s shares (diluted) increased by 6.2% year-over-year, from 59.4M to 63.1M.
- What is the long-term trend for Stoke Therapeutics, Inc.'s shares (diluted)?
- Over 4 years (2021 to 2025), Stoke Therapeutics, Inc.'s shares (diluted) has grown at a 12.6% compound annual growth rate (CAGR), from 146.8M to 235.6M.
- What does shares (diluted) mean?
- The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.
Ask your AI about Stoke Therapeutics, Inc.'s shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude